Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC decreased its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 4.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 157,992 shares of the company’s stock after selling 7,096 shares during the quarter. Voya Investment Management LLC owned 0.26% of Twist Bioscience worth $7,342,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of TWST. Van ECK Associates Corp lifted its stake in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after acquiring an additional 267 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience during the third quarter valued at $34,000. US Bancorp DE grew its position in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after purchasing an additional 601 shares during the period. Beaird Harris Wealth Management LLC purchased a new position in shares of Twist Bioscience during the 3rd quarter valued at about $95,000. Finally, KBC Group NV raised its stake in shares of Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after buying an additional 1,226 shares during the last quarter.

Wall Street Analyst Weigh In

TWST has been the subject of a number of analyst reports. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Guggenheim set a $50.00 price target on shares of Twist Bioscience in a research note on Friday, March 28th. Robert W. Baird boosted their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. Barclays decreased their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.80.

Insider Activity at Twist Bioscience

In related news, Director Robert Chess sold 2,940 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $53.13, for a total value of $156,202.20. Following the sale, the director now directly owns 18,173 shares in the company, valued at approximately $965,531.49. The trade was a 13.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dennis Cho sold 806 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the transaction, the insider now directly owns 112,221 shares in the company, valued at $5,538,106.35. The trade was a 0.71 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,432 shares of company stock valued at $1,038,170. 3.01% of the stock is owned by company insiders.

Twist Bioscience Trading Down 0.6 %

Shares of Twist Bioscience stock opened at $39.68 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The stock’s 50 day simple moving average is $39.40 and its 200-day simple moving average is $44.22. The stock has a market cap of $2.37 billion, a P/E ratio of -11.74 and a beta of 2.34. Twist Bioscience Co. has a 1-year low of $30.32 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same quarter in the previous year, the company posted ($0.75) earnings per share. The firm’s revenue for the quarter was up 24.1% compared to the same quarter last year. Analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.